Although the rodent bone marrow micronucleus test has been in routine use for over 20 years, little work has been published to support its experimental design and all this has used the mouse rather than the rat. When it was decided to change the strain of rat routinely used in this laboratory to the Han Wistar, a preliminary study was performed to investigate the possible factors influencing experimental variability and to use statistical tools to examine possible study designs. Subsequently, a historical database comprising of vehicle controls accumulated from 65 studies was used to establish test acceptance criteria and a strategy for analysing equivocal results. The following conclusions were made: (i) no statistically significant differences were observed in experimental variability within or between control animals; although not statistically significant, the majority of experimental variability seen was found to be between separate counts on the same slide, with minimal differences found between duplicate slides from the same rat or between individual rats; (ii) power analyses showed that, if an equivocal result is obtained after scoring 2000 immature erythrocytes (IE), it is appropriate to re-code the slides and score an additional 4000 IE, i.e. analysing a total of 6000 IE; no meaningful increase in statistical power is gained by scoring >6000 IE; this is consistent with the variability observed between separate counts on the same slide; (iii) there was no significant difference between the control micronucleated immature erythrocyte (MIE) values at 24 and 48 h after dosing or between males and females; therefore, if an unusually low control value at either time point results in apparent small increases in MIE in a treated group, it is valid to pool control values from both time points for clarification and (iv) similar statistical power can be achieved by scoring 2000 IE from seven rats or 4000 IE from five rats, respectively. However, this is based only on control animals and does not consider possible differences in responses between animals to treatment with a potential genotoxin. In order to minimize the possible influence of responders and nonresponders, the preferred study design in this laboratory is to score 2000 IE from groups of seven rats. Study data obtained over time confirmed observations made in the control study. Also from an ethical viewpoint, clarifying equivocal responses by combining control data from the 24-and 48-h time points and/or increasing the number of IE scored per animal has minimized the numbers of repeat studies necessary to determine the genotoxic status of a novel compound. However, before any laboratory can use these procedures, experimental data must be generated to demonstrate their validity.
Introduction
The rodent bone marrow micronucleus test has been widely used as a screening procedure to detect potential chromosome damaging agents and/or aneugens for over 20 years (1) but, during this time, little work has been published to support its experimental design. Most guidelines initially recommended 10 animals per group and 1000 immature erythrocytes (IE) to be scored per animal for both rats and mice (2) but it was later concluded that analysis of 2000 IE per animal would allow a reduction in group size without loss of test sensitivity (3). Mirkova and Ashby (4) also noted that increased power could be achieved by extending the number of cells scored but did not recommend a number in relation to the statistical power of the assay. Subsequently, it was suggested that, for mice, assessment of 2000 IE per animal was optimum with little further advantage gained by scoring 3000 IE (5) . The variability of data in the mouse micronucleus assay was considered by Mitchell et al. (6) in relation to the importance of ''outliers'' in control and treated groups and the same authors applied statistical analysis to the use of historical data to clarify statistically significant but biologically unimportant results (7). Hayashi et al. (8) suggested a procedure for analysis using historical control data to assess assay validity and a trend test to determine the significance of possible dose relationships. However, all these studies used data from mice and similar analyses do not appear to have been published for the rat. Kissling et al. (9) used flow cytometry as an alternative to microscopy for scoring micronucleated erythrocytes in the peripheral blood of mice, rats and dogs and in the bone marrow of rats. They concluded that the number of reticulocytes scored should reduce the counting error to less than the variability between animals, which could be achieved by this method by analysing up to 20 000 reticulocytes.
Some time ago, it was decided to change to the Han Wistar rat for routine use in this laboratory, but before testing compounds for regulatory submission purposes, it was necessary to establish the control micronucleus ranges. Whilst performing this exercise, it was decided to investigate all the factors contributing to variability in order to provide a statistical justification for the study design. Analysis of the control data accumulated subsequently was then used to establish criteria for test acceptability and clarification of equivocal results for studies performed in this laboratory.
Materials and methods
All chemicals and reagents were purchased from Sigma (Dorset, UK) unless specified.
Animal husbandry and treatment
Male and female Han Wistar rats (substrain Crl:WI(Glx/BRL/Han)IGSBR) obtained initially from Charles River, UK, then subsequently from the AstraZeneca breeding unit, were $9-10 weeks old at dosing and were housed three or four per cage. Environmental controls were set to maintain conditions of 19-23°C and 40-70% relative humidity, with a 12-h light/dark cycle. All animals were treated in accordance with approved UK Home Office licence requirements.
Bone marrow micronucleus test
In the control study, rats were given single oral doses (dose volume 10 ml/kg) and sacrificed 24 or 48 h later by halothane administration and cervical dislocation. Historical studies conducted between the end 2002 to the end 2007 were also single-dose protocols followed by two sample times; however, studies conducted between the end 2007 and the end 2008 were dosed using the two-dose regimen 24 h apart and sacrificed 24 h after the second dose. The femur of one leg was removed from each rat, the ends clipped to expose the bone marrow and smears prepared and stained essentially as described by Tinwell and Ashby (10) . The femoral cells were flushed out with foetal bovine serum containing 25 mmol/litre ethylenediaminetetraacetic acid, filtered through a 150-micron bolting cloth and centrifuged at 200 Â g for 5 min. The supernatant was removed, the cell pellet carefully mixed by repeated aspiration with a Pasteur pipette and a small drop spread onto a clean microscope slide, air-dried and then fixed with methanol. After drying again, slides were dipped in fresh phosphate buffer, pH 6.4, stained with 12.5% acridine orange, then rinsed in two changes of fresh phosphate buffer and airdried. Prior to analysis, slides were coded, wet mounted in phosphate buffer and examined blind by fluorescence microscopy at Â400 magnification. Mature erythrocytes with cytoplasm stained dull khaki-green colour, IE stained bright red/orange and micronucleated immature erythrocytes (MIE) were scored.
Prospective study examining factors influencing experimental variability Groups of seven male and seven female rats were given single oral doses of HPMC (water containing 1% hydroxypropyl methylcellulose in 0.1% w/v polysorbate 80), 20 mg/kg cyclophosphamide (CPA) dissolved in purified sterile water for injection or left untreated (untreated control). All groups were sampled at 24 and 48 h after dosing, except those given CPA which were examined only at 24 h. The CPA group was included in order to prepare additional sets of positive slides for using in future studies which do not have a concurrent positive control group. The positive slides serve as controls for the staining and scoring procedures as discussed in Hayashi et al. (11) . The study was repeated 3 weeks later, identical in all respects except that the CPA group was omitted. These two parts of the study are referred to as the 'phase' of the study.
In both parts of the study, duplicate slides were prepared from each rat and were scored by two independent scorers who were each assigned one of the duplicates. From each slide, two counts of 2000 IE were scored for micronucleus incidence, i.e. a total of 4000 IE per slide and 8000 IE per rat. Previous training and blind comparisons had established that there was no significant difference in results obtained by the individual scorers.
To achieve an approximately normal distribution, statistical analyses were conducted on square root-transformed data (3). The average square root transformation was selected because it is known to stabilize the variance more effectively when some of the counts are small (12) , as is generally the case with data from this laboratory.
The effect of the number of slides and the number of IE counted per slide was explored using scatter-plots by plotting the four counts and performing cross-tabulations and analysis of variance (ANOVA). The effect of other factors, i.e. of sex, phase, vehicle control or untreated, and 24-or 48-h time point, was investigated using ANOVA; the four counts were treated as repeat measures within an animal, and 'animal' was fitted as a random-effect term in the model. A variance components model was used to estimate the betweenand within-animal variability, while taking account of variability due to the factors listed above. These estimates were then used to calculate the pooled standard error, which was subsequently used in power analysis; the power of a statistical test can be thought of as the chance of detecting a compound effect of a given size if such an effect exists. It is dependent on the inherent variability of the data and how this is split between and within animals (as estimated from the variance components), group sizes and the number of IE scored per animal. Power was estimated for one-sided t-test at the 5% level on transformed counts to detect a doubling in the mean number of MIE from one to two per group, using the non-central t distribution (13, 14) .
Bootstrap re-sampling was used to estimate the population distribution of mean MIE. The 2.5 and 97.5 centiles were used to estimate a reference interval. Bootstrapping is a simulated method of making inferences about the mean, standard deviation (SD), quartiles and other parameters of the distribution, by sampling from the data gathered. It is particularly useful in cases where the actual distribution of the data is complex. Bootstrap samples were arbitrarily drawn from count 1 on slide A as most studies would have one count per slide per animal.
Studies contributing to the historical database Data from 65 individual tests performed over a 5-year period contributed to the historical database. Of these studies, 51 used single doses with two sample times and 14 used two doses and a single sample time protocols; however, no alteration in mean and acceptance limits occurred when moving between protocols for dosing. All consisted of control groups of seven male Han Wistar rats (substrain AlpkHsdRccHan-WIST) given oral gavage doses, and in the majority of these, the vehicle was HPMC. Rats for the first 19 studies were purchased from Charles River, UK, and those used subsequently were supplied by the AstraZeneca breeding unit. Groups were sacrificed 24 and 48 h after a single dose or 24 h after two doses given 24 h apart and 2000 IE scored for each rat. In cases where extended counts were required, the slides were recoded and a further 4000 IE scored per slide. All data from both initial and extended counts are expressed as the number of MIE in 2000 IE.
Data from three studies on AstraZeneca proprietary compounds were used to illustrate the statistical analyses.
Results

Factors influencing experimental variability
Variability between and within slides. Variability between and within slides was assessed by plotting the MIE data for each animal in scatter-plots representing the duplicate slides prepared for each animal. The two scatter-plots were then visually examined to determine correlations between two counts within each slide and between the two slides. Visual assessment of the scatter-plots showed no discernible correlation between counts within a slide or counts between slides.
Variability between sexes, treated and untreated controls and sampling time. A variability plot of square root-transformed MIE data was initially used to investigate evidence of any difference between sexes, phase, untreated or treated control and 24-or 48-h sample times (Figure 1) . None of these factors appeared to have any significant effect on mean MIE counts, and this was confirmed in the formal statistical model. In addition, second-order interactions were examined to determine if one factor was influenced by another. All secondorder interactions failed to reach statistical significance.
Since there is no significant difference between the MIE values at 24 and 48 h in the control study, it was concluded that it is valid to combine data from both time points and to reapply the statistical analysis in studies where a low control is obtained at either time point.
Variability within and between animals. Variance components were estimated by pooling all data as it had been shown that phase, sex, control type and time point were not statistically different. However, variability is present and the most were observed within and not between individual animals (Table I) .
Power analyses to determine optimal experimental design The power of a one-sided t-test to detect a doubling in the mean number of MIE from one to two per group was estimated for varying group sizes (5, 6, 7 and 10 rats) and number of IE scored per animal (2000, 4000, 6000, 8000 and 10 000) shown in Figure 2 .
The statistical power of a study with seven animals per group and 2000 IE scored per animal is $74%, similar to scoring 4000 IE from five animals (80%). By increasing the cell count to 6000 IE, a group size of seven animals would give a power of $97%. This power estimation demonstrated that, if a result is equivocal after scoring 2000 IE per rat, it is appropriate to extend the analysis to 6000 IE. However, no meaningful increase in power is gained by scoring .6000 IE.
Reference intervals Prospective study. The estimated reference intervals for all group means in the control study (seven animals per group and 2000 IE per animal) were 0.25-1.65 MIE/2000 IE with an overall mean of 0.96 MIE. However, this control study was not expected to capture all study-to-study variability, and analysis of the historical database was performed to give a more accurate estimate of the reference intervals.
Analysis of historical control data. The control chart (Figure 3) shows the mean data from 116 control groups, each comprising of seven rats, and plotted in chronological order. Mean control group data were added to the chart on completion of each individual study and an overall historical mean calculated. This methodology, as described, by Wheeler and Chambers (15) was also used to calculate the expected upper and lower limits, which are set at AE3 SDs from the mean. The SD used in control charts is not calculated in the traditional way (using squared differences from the mean), but instead uses moving ranges and as a consequence is robust to the presence of exceptional variation (due to assignable cause) in the data. As the limits are based on non-parametric methods (i.e. no distributional assumptions are made), it is not possible to attach exact probabilities to them; however, given that there are no changes to the assay process, which would cause a result to be outside the limits, at least 99% of results would be expected to fall within them. A control group mean outside these limits indicates that the study or, the animals used in the study, are unusual in some way.
Initially, acceptance limits of 0.60-3.49 MIE per 2000 IE with an overall historical mean of 1.98 MIE were calculated for rats supplied by Charles River, UK. A reduction in the The control data for studies conducted in this laboratory in 2007 are shown in Figure 4 , with the 24-and 48-h group means plotted for each individual study. When average square roottransformed individual animal counts rather than group means are examined, there is no significant difference (P 5 0.09) between time points; therefore, it was concluded that combining data from the two time points in this study design is valid.
Practical application
Results of three studies with AstraZeneca proprietary compounds (X, Y and Z) illustrate the application of the statistical analyses described above.
Compound X. There was a small but statistically significant increase in the incidence of MIE (P , 0.05) at the 48-h sampling time. The control group mean was within the acceptance limits for a valid study, but at the lower end of the range, and the treated group was also within the historical control range. The 24-and 48-h control data were then combined and, using a pairwise comparison, the small increase in the treated group was found not to be statistically significant (Table II) .
Compound Y. In the initial analysis, a small but statistically significant increase was observed at the 48-h sample time (P , 0.05). The concurrent control group mean was within the acceptance limits; therefore, further statistical and microscopic analyses were conducted. First, the 24-and 48-h control data were combined and the pairwise analysis for the 48-h treated group was re-calculated. The result remained statistically borderline (P 5 0.0515); therefore, another 4000 IE per animal were scored (6000 IE in total). The increase was no longer statistically significant (P . 0.05) and was considered to be of no biological relevance since all control and treated group mean values data fell within the historical control acceptance limits (Table III) .
Compound Z. At the 24-h time point, the initial 2000 IE count resulted in a significant trend (P , 0.01) across the dose groups. The MIE counts for all groups were within the historical range but the group mean MIE value for the highest dose level was just above the upper acceptance limit for control values. To clarify this finding, the analysis was extended to a total of 6000 IE and the incidence of MIE was significantly increased with a trend over all the dose groups (P , 0.01). The trend test was re-applied in a cascade excluding sequentially the top and intermediate doses. When the top dose was excluded, the trend across the remaining groups was still significant, and the no effect level was found at the lowest dose. Analysis of variance with contrasts for pairwise comparisons was also significant at the intermediate and top doses. The incidences of micronuclei at these dose levels were outside the historical acceptance limits and were associated with a dose-response; therefore, the result was considered to be weakly positive with a no observable effect level of 10 mg/kg (Table IV) .
Discussion
When introducing a new rat strain into a laboratory, it cannot be assumed that different strains behave alike and, therefore, it is essential to establish control MIE levels and acceptable limits prior to undertaking pivotal assays. The statistical analyses performed here allowed the following conclusions to be drawn about the conduct of the bone marrow micronucleus test using Han Wistar rats in this laboratory.
1. No significant experimental variability was seen within or between control animals. Although not statistically significant, the majority of experimental variability seen was found to be between separate counts on the same slide, with minimal differences found between duplicate slides from the same rat or between individual rats. 2. Power analyses showed that, if an equivocal result is obtained after scoring 2000 IE, it is appropriate to re-code the slides and score an additional 4000 IE, i.e. analysing a total of 6000 IE. No meaningful increase in statistical power is gained by scoring .6000 IE. This is consistent with the majority of variability being between separate counts on the same slide. However, other analysis methods such as flow cytometry have shown increased sensitivity when more cells are examined, e.g. 20 000 reticulocytes (9).
3. There was no significant difference between the control MIE values at 24 and 48 h after dosing for either males or females. Therefore, if an unusually low control value at either time point results in apparent small increases in MIE in a treated groups, it is valid to pool control values from both time points and sexes for clarification. 4. Similar statistical power can be achieved by scoring 2000 IE from seven rats or 4000 IE from five rats, respectively. However, this is based only on control animals and does not consider possible differences in responses between animals to treatment with a potential genotoxin. In order to minimize the possible influence of responders and non-responders, the preferred study design in this laboratory is to score 2000 IE from groups of seven rats. If a study were conducted using both sexes, it would be acceptable to reduce the animal size to 5 animals/sex/group and combine the control group, as we have shown that there is no difference in control levels of MIE between males and females.
From an ethical viewpoint, clarifying equivocal responses by combining control data from the 24-and 48-h time points and/ or increasing the number of IE scored per animal has minimized the numbers of repeat studies necessary to determine the genotoxic status of a novel compound. This approach has been employed in seven micronucleus studies in which further clarification of results was required, resulting in a substantial saving in animal numbers. The same approach has also been applied to what is now the preferred micronucleus dosing regimen, i.e. two doses with a single sample point and, out of 14 studies, extended analysis has been performed on two to clarify equivocal results. Perhaps, unsurprisingly, the data from single-dose and two-dose protocols show directly similar variability confirming that the same statistical procedures are applicable to both. Although two doses are now routinely used in this laboratory for micronucleus tests using oral gavage administration, the single-dose protocol is retained for use for other routes of administration, e.g. intravenous infusion. However, before any laboratory can use these procedures for either experimental design, data must be generated to demonstrate their validity.
Furthermore, although integrating the bone marrow micronucleus test into pivotal toxicity studies is being suggested in the revision International Conference on Harmonisation S2 guidelines (16) , it would seem critical for laboratories to establish their control databases to determine whether such Rat micronucleus study design integrated studies have similar power and can be analysed using the same statistical methods as acute studies. Finally, if other end-points are to be assessed in the same or parallel studies, it would seem sensible to demonstrate that the experimental designs give similar statistical power, as has been shown for the rat comet assay in this laboratory (17) .
